PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

This study looks at how safe and helpful a special medicine called **PD-1 antibody** is, together with other medicines like **bevacizumab** and **chemotherapy**, for treating a type of colon cancer called **metastatic colorectal cancer (mCRC)**. This cancer is when cancer cells have spread from the colon to other parts of the body. The study is for people whose cancer has a **RAS mutation** and is **microsatellite stable (MSS)**, meaning the DNA in cancer cells does not have tiny repeats that make it unstable. Before joining, patients shouldn't have had any treatment for their spreading cancer, and they need to be in pretty good health (ECOG status 0-1). They also need to have at least one measurable tumor. Some health checks, like blood tests, are important to ensure the body can handle the treatment.

• **Study Length**: Not mentioned, but prepare for multiple visits and tests.
• **Risks**: Includes reactions to medication, possible infections, or other side effects.
• **Important**: Women need to use birth control, and certain health conditions may exclude participation.